Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | CASP1 | P29466 | 1/20 | 0.68 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.68 |
| ▸ | CASP7 | P55210 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | FLT3 | P36888 | 3/20 | 0.67 |
| ▸ | CLK1 | P49759 | 2/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.59 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2811008 | 0.88 | KDM4E (0.53) | LMNAALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL1068608 | 0.87 | FLT3 (0.67) | LMNAALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL211674 | 0.83 | FLT3 (0.67) | LMNAALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL1065473 | 0.83 | TAS1R3 (0.55) | LMNAALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL1473963 | 0.83 | MAOB (0.68) | LMNAALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL24681539 | 0.82 | TAS1R3 (0.57) | ALDH1A1HPGDHSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL22276177 | 0.82 | CHRNA7 (0.47) | LMNAALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL1066370 | 0.82 | PIM1 (0.66) | LMNAALDH1A1SMN1; SMN2TP53MAOA | |
| SCHEMBL446971 | 0.82 | TAS1R3 (0.64) | ALDH1A1HPGDHSD17B10KDM4EGAA | |
| Hydrochloric Acid SCHEMBL6985335 | 0.82 | FLT3 (0.65) | LMNAALDH1A1HPGDHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112543764-B | Amide compound with BET proteolytic induction effect and medical application thereof | 田边三菱制药株式会社 | 2024-05-10 | — | — | CN | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3819305-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | disclosed |
| CN-112543764-A | Amide compound with BET proteolysis induction effect and medical application thereof | 田边三菱制药株式会社 | 2021-03-23 | — | — | CN | disclosed |
| US-9186347-B1 | Hydroxamates as therapeutic agents | PHARMACYCLICS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| CN-102391222-B | As the hydroxamic acid ester of therapeutical agent | PHARMACYCLICS INC. (US) | 2015-10-21 | — | — | CN | disclosed |
| EP-0703911-B1 | SECONDARY AMINES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | PFIZER (US) | 1997-07-02 | — | — | EP | disclosed |
| US-5627200-A | β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia | PFIZER INC (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0733631-A1 | Benzofuran derivates useful as hypoglycemic and hypolidemic agents | Takeda Chemical Industries, Ltd. (JP) | 1996-09-25 | — | — | EP | disclosed |
| CN-1129443-A | Secondary amines as antidiabetic and antiobesity agents | PFIZER (US) | 1996-08-21 | — | — | CN | disclosed |
| EP-0703911-A1 | SECONDARY AMINES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | PFIZER (US) | 1996-04-03 | — | — | EP | disclosed |
| WO-1994029290-A1 | SECONDARY AMINES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | PFIZER INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| EP-0061800-B1 | ANTI SRS-A CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | FISONS plc (GB) | 1985-08-28 | — | — | EP | disclosed |
| US-4518612-A | Naphthalene and 2-oxo-benzopyran acids and derivatives and pharamaceutical use thereof | FISONS PLC (GB) | 1985-05-21 | — | — | US | disclosed |
| US-4424231-A | Compounds | FISONS LIMITED (GB) | 1984-01-03 | — | — | US | disclosed |
| EP-0061800-A1 | Anti SRS-A carboxylic acid derivatives, processes for their production and pharmaceutical formulations containing them | FISONS plc (GB) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | LMNA 2073/4885ALDH1A1 4054/4885HPGD 2911/4885 |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | LMNA 2695/4885ALDH1A1 871/4885HPGD 122/4885 |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | BET1, BRD4, PHKB | LMNA 1941/4885ALDH1A1 4055/4885HPGD 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.